ClinVar Miner

Submissions for variant NM_000546.6(TP53):c.139C>T (p.Pro47Ser) (rs1800371)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 15
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
ClinGen TP53 Variant Curation Expert Panel,ClinGen RCV000991144 SCV001142551 benign Li-Fraumeni syndrome 2019-08-28 reviewed by expert panel curation This variant has a minor allele frequency of 0.01645 (1.6%, 410/24,922 alleles) in the African subpopulation of the gnomAD cohort (BA1). The variant has a BayesDel score < 0.16 and Align GVGD (Zebrafish) is Class C0 or Class C15 (BP4). Additionally, transactivation assays show supertransactivation function according to Kato, et al. and there is no evidence of a dominant negative effect or loss of function according to Giacomelli, et al. (BS3; PMID: 12826609, 30224644). Finally, this variant has been observed in at least 105 60+ year old females without a cancer diagnosis (BS2; FLOSSIES database - In summary, TP53 c.139C>T; p.Pro47Ser meets criteria to be classified as benign for Li-Fraumeni syndrome. ACMG/AMP criteria applied, as specified by the TP53 Variant Curation Expert Panel: BA1, BP4, BS3, BS2.
Laboratory for Molecular Medicine,Partners HealthCare Personalized Medicine RCV000036530 SCV000060185 uncertain significance not specified 2011-09-23 criteria provided, single submitter clinical testing The Pro47Ser variant in TP53 is a common polymorphism in individuals with Africa n ancestry and has an observed minor allele frequency ranging from 2.2 - 6.7% in Yorubans (HapMap and 1000 Genomes; Felley-Bosco 1993). This polymorphism has a lso been observed in Brazilian and Kashmiri populations with gliomas, bladder an d colorectal cancer (Pinto 2008, Sameer 2010, Santos 2011). Despite the common nature of this polymorphism, there have been extensive functional studies sugges ting the Pro47Ser change has functional consequences and associated with increas ed cancer susceptibility; however, the data and consensus is variable (Olivier 2 010). The proline at position 47 lies adjacent to a functionally important prol ine-rich region (amino acids 64-92) and the adjacent serine at position 46 has b een reported to be an important phosphorylation site necessary for p53-dependent apoptotic activity (Pistritto 2007). Moreover, functional studies suggest the Pro47Ser variant has decreased activity to transactivate downstream apoptotic ef fector molecules (Li 2005; Whibley 2009). Proline at position 47 is poorly cons erved in vertebrate organisms and absent from more distantly related organisms, suggesting a benign role. The variant has never been reported in a family with Li Fraumeni syndrome. Although this variant is a common polymorphism, the clinic al significance of it, particuarly in the homozgyous state, cannot be determined at this time.
GeneDx RCV000036530 SCV000169027 benign not specified 2013-10-08 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Ambry Genetics RCV000131567 SCV000186571 benign Hereditary cancer-predisposing syndrome 2014-11-18 criteria provided, single submitter clinical testing General population or subpopulation frequency is too high to be a pathogenic mutation based on disease/syndrome prevalence and penetrance;In silico models in agreement (benign)
Pathway Genomics RCV000172826 SCV000223792 benign Li-Fraumeni syndrome 1 2014-10-30 criteria provided, single submitter clinical testing
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000036530 SCV000230122 benign not specified 2014-09-29 criteria provided, single submitter clinical testing
Invitae RCV000991144 SCV000261827 benign Li-Fraumeni syndrome 2020-12-08 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics,ARUP Laboratories RCV000590436 SCV000605423 benign not provided 2017-10-31 criteria provided, single submitter clinical testing
Color Health, Inc RCV000131567 SCV000686719 benign Hereditary cancer-predisposing syndrome 2015-08-13 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000590436 SCV000697429 benign not provided 2017-08-22 criteria provided, single submitter clinical testing Variant summary: The TP53 c.139C>T (p.Pro47Ser) variant located in the transactivation domain involves the alteration of a non-conserved nucleotide and 3/5 in silico tools predict a benign outcome for this substitution. his variant was found in 436/277308 control chromosomes, predominantly observed in the African subpopulation at a frequency of 0.016374 (393/24002). This frequency is about 412 times the estimated maximal expected allele frequency of a pathogenic TP53 variant (0.0000398), suggesting this is likely a benign polymorphism found primarily in the populations of African origin. In addition, case-control studies also show that this variant does not confer an associated cancer risk. Despite the common nature of this polymorphism, functional studies are inconclusive as to whether the variant has functional consequences. Some studies (Li_ 2005, Rigacci_2008, Jennis_ 2014 and Jennis_2016) have shown that this variant leads to functional impairment, while Wasserman_2015 indicates the variant has an additive affect, suggesting a notion that this variant is a functional polymorphism. The proline at position 47 lies adjacent to a functionally important proline-rich region (amino acids 64-92) and the adjacent serine at position 46 has been reported to be an important phosphorylation site necessary for p53-dependent apoptotic activity. A functional sudy published showed that human and mouse cells expressing the S47 variant are markedly resistant to cell death by agents that induce ferroptosis (ironmediated nonapoptotic cell death) and that mice expressing S47 in homozygous or heterozygous form are susceptible to spontaneous cancers of diverse histological types. Based on these observations Jennis_2016 suggested that the S47 variant may contribute to increased cancer risk in individuals of African descent. However, multiple clinical diagnostic laboratories have cited the variant as Benign. Furthermore, the variant of interest has been found to co-occur with multiple pathogenic variants, PTEN c.406T>C (p.Cys136Arg) and BRCA1 c.213-12A>G and likely pathogenic MLH1 variant, c.1731+1G>T (2 individuals). Taken together, their is a discrepancy between the clinical observations (co-occurrence with other pathogenic/likely pathogenic variants, and large excess in the control cohort) and functional data, where a correlation between the measured property and the disease physiology has not been clearly established. Therefore, this variant is classified as "Benign".
PreventionGenetics,PreventionGenetics RCV000036530 SCV000806234 benign not specified 2016-11-22 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000172826 SCV001282025 benign Li-Fraumeni syndrome 1 2018-06-08 criteria provided, single submitter clinical testing This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to rule this variant out of causing disease. Therefore, this variant is classified as benign.
ITMI RCV000036530 SCV000086396 not provided not specified 2013-09-19 no assertion provided reference population
Mayo Clinic Laboratories, Mayo Clinic RCV000590436 SCV000692095 benign not provided 2018-02-09 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine,Sinai Health System RCV001355028 SCV001549786 benign Malignant tumor of breast no assertion criteria provided clinical testing The TP53 p.Pro47Ser variant was identified in 41 of 5182 proband chromosomes (frequency: 0.01) from individuals or families with breast cancer, brain tumour, gliomas, bladder cancer or Lynch syndrome and was present in 6 of 2858 control chromosomes (frequency: 0.002) from healthy individuals (Alawadi 2011, Almeida 2009, Bodian 2014, Cock-Rada 2017, Pinto 2008, Sameer 2010, Yurgelun 2015). The variant was also identified in dbSNP (ID: rs1800371) as ‚ With Uncertain significance, other allele‚Äù, ClinVar (as benign by GeneDx, Ambry Genetics, Pathway Genomics, EGL Genetic Diagnostics, Invitae, ARUP, Color Genomics, Integrated Genetics, and Mayo Clinic and as uncertain significance by Laboratory for Molecular Medicine), Cosmic (3x found in liver, endometrium and kidney cancer), LOVD 3.0 (1x), and in IARC TP53 (as neutral). The variant was not identified in the Database of germline p53 mutations. The variant was identified in control databases in 433 of 277106 chromosomes (3 homozygous) at a frequency of 0.002 increasing the likelihood this could be a low frequency benign variant (Genome Aggregation Database Feb 27, 2017). The variant was observed in the following populations: African in 393 of 24002 chromosomes (freq: 0.02), Other in 4 of 6464 chromosomes (freq: 0.001), Latino in 30 of 34412 chromosomes (freq: 0.001), European in 4 of 126662 chromosomes (freq: 0.00003), and South Asian in 2 of 30780 chromosomes (freq: 0.0001); it was not observed in the Ashkenazi Jewish, East Asian, and Finnish populations. The p.Pro47 residue is not conserved in mammals and four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; however, this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. The Pro47Ser polymorphism has a significant influence on p53 function, by reducing phosphorylation on serine 46 and impairing p53 apoptotic and transcriptional functions (Olivier 2010, Li 2005) in mouse embryo fibroblasts (Basu 2016,). The functional study of the p53 transactivation domain aggregates in vitro showed aggregation propensity of the Pro47Ser mutated peptide have the same rate as the wild type (Rigacci 2008). In another study (Cock-Rada 2017) the variant was identified with a co-occurring pathogenic BRCA1 variant, suggesting the Pro47Ser variant may not have clinical significance. Association of Pro47Ser polymorphism was not observed in bladder (Santos 2011), gliomas (Pinto 2008), colorectal cancer (Sameer 2010), and breast cancer (Alawadi 2011, Sharma 2014). In addition, the meta-analysis of 11 case-control studies by Chandel (2013) concluded that published results seem to be driven by technical artifacts rather than justified biological effects. This systematic review and meta-analysis of genetic association studies shows that TP53 p.Pro47Ser is unlikely to be a major risk factor for different types of cancers and many diseases. In summary, based on the above information this variant meets our laboratory's criteria to be classified as benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.